Key Takeaways
- 23% like-for-like growth, highest ever quarterly profit: Q4 FY24 delivered INR30 crores PAT and INR80 crores free cash flow, with EBITDA swinging from negative last year to 7% this quarter.
- Distribution transition is a deliberate, temporary drag: Moving from super stockists to direct distributors in top cities shaved ~200 bps off primary sales in Q4, and management expects 50-100 bps impact per quarter for the next three quarters.
- House of Brands engine is scaling: Derma Co hit an INR500 crores ARR, the sunscreen portfolio captured >30% ecommerce share, and STAZE entered colour cosmetics, all while NPD contributed 18% of FY24 revenue.
- Margins have a clear, multi-lever path up: FY24 EBITDA reached 7.1%, and management is targeting at least 150 bps improvement in FY25 from gross margin mix, A&P efficiency as brands scale, and operating leverage.
- What to watch next quarter: Whether the distribution transition impact stays within the guided 50-100 bps band, the pace of Mamaearth's offline-driven double-digit value growth, and closure of the Cosmogenesis Labs acquisition.
Distribution Transition: The Deliberate Topline Headwind
- Mechanics of the shift: The company is replacing super stockists with direct distributors across the top 50 cities, a move that started in Q3 FY24 and was expedited in Q4. Super stockists previously charged a 5% distribution cost premium, so the transition improves unit economics over time at the expense of near-term primary sales.
- Quantified drag: The transition impacted primary sales by ~200 bps in Q4 FY24. Management expects a 50-100 bps impact per quarter over the next three quarters, with the objective of reducing the super stockist layer from 50% to 30% of distribution.
- Why it matters strategically: Direct distribution gives the company more control over in-store execution and access to the data needed for offline decision-making, a capability management now sees as essential after learning that offline success demands the same data richness as online.
Varun Alagh: "the impact that we are seeing is in our primary sales, which is what I talked about, for example, last quarter, about 200 basis points in primary sales is the impact over the next three quarters, we believe 50 to 100 basis points every quarter will be the impact on this"
Mamaearth: The Core Brand's Growth Algorithm
- Market share momentum: Mamaearth was the fastest-growing brand among the top 15 BPC brands in India per Euromonitor 2023, growing at 21% versus a 7% category average. It gained 120 bps in face wash and 40 bps in shampoo per Nielsen, with handler share up 150 bps and 65 bps respectively.
- The UVG-value growth gap explained: Mamaearth's volume growth ran in the mid-teens in FY24 while value growth was shy of 10%. The gap is a channel-mix artifact: B2B channels (offline, modern trade) carry lower per-unit revenue recognition than B2C, so more units are needed to generate the same revenue. Management expects this gap to close as the distribution transition normalizes.
- Hero SKU-led offline play: Growth is increasingly coming from offline and modern trade, where a concentrated set of hero SKUs like Ubtan Face Wash and Onion Shampoo grew in high double-digits in value last year. The plan is to sustain double-digit value CAGR for Mamaearth over the next two years.
- LUP strategy with an aspirational guardrail: The company is scaling INR99 price-point packs in shampoo and face washes this year and may explore INR49-50 levels next year, but explicitly rules out sachets. Management frames this as a "MUP" (medium unit pack) strategy to preserve brand aspiration.
Varun Alagh: "I must clarify that our LUP is largely actually categorized as MUP. Because we will not get into sachets as a company, given we have aspirational brands, and we would like to maintain that aspiration."
House of Brands: Scaling Beyond the Flagship
- Derma Co milestone: The brand crossed an ARR of INR500 crores (net sales value) in Q4, with GMV close to INR900 crores, and is profitable. Launched in March 2020, it is the first non-Mamaearth brand to reach this scale.
- Sunscreen category dominance: Honasa's multi-brand strategy captured >30% market share across ecommerce platforms in sunscreen, with differentiated propositions: Mamaearth (natural), Derma Co (active), Aqualogica (hydrating), and Dr. Sheth's (bioactive). At least three Honasa brands feature in the top five on Amazon and Nykaa.
- STAZE enters colour cosmetics: The company launched STAZE, a Gen Z-focused colour cosmetics brand, with a 3-in-1 lipstick and Tubing Mascara, both positioned as new-to-world innovations.
- Long-term brand ambitions: Over the next 3-5 years, management targets Derma Co entering the INR1,000 crores club, Aqualogica and Dr. Sheth's entering INR500 crores, and BBlunt entering INR250 crores.
- New brand creation philosophy: Management will launch a new brand only when an opportunity requires a sharp, distinct architecture that existing brands cannot stretch to cover, citing its proven ability to create value by building brands from scratch.
Varun Alagh: "if there is an opportunity to disrupt, and that disruption cannot be done by one of our existing brands because of the because of the sharpness or architecture required to do it then we would surely look at newer brands to cater to that because we have proven our ability to create value by building a newer brand."
Margin Expansion: The 150 bps Roadmap
- FY24 base built: Full-year EBITDA improved from 1.5% in FY23 to 7.1% in FY24, driven by efficiencies in A&P, opex, and other costs without compromising brand building. PAT reached INR111 crores with INR224 crores in free cash flow.
- Three levers for FY25: The targeted 150 bps margin expansion will come from slight gross margin improvement as younger brands with better gross margin profiles scale, A&P percentage declining as brands mature, and opex and other costs growing slower than company revenue.
- Quarterly variance contained: Management expects margin variance across quarters in FY25 to stay within a 50-70 bps range, implying a relatively steady climb rather than lumpy swings.
- Innovation as the growth engine: NPD contributed 18% to FY24 revenue, and management expects at least 40-50% of future growth to be driven by innovations, which typically carry healthier margins.
Competitive Posture & Quality Moat
- Incumbent discounting pressure: Large incumbents are increasing competition online through significantly higher discounting. Management's counter-argument is that beyond a certain price level, consumer choice in BPC is brand-driven, not price-driven, so the company remains confident in delivering its goals.
- Quality as a structural advantage: The company conducted over 20,000 tests on each manufactured batch last year. Management describes a culture of "quality paranoia" rooted in the brand's baby-care origins, where founders tested products on their own children and still personally test everything.
- R&D acquisition deepens the moat: The acquisition of Cosmogenesis Labs brings 25 years of formulation expertise (5,000+ formulations), R&D labs, and a nano-manufacturing facility. The founder, Rohini Manoj, joins as VP of R&D. The deal is expected to close in 4-6 weeks and is designed to accelerate the innovation targets already set internally, not to create separate targets.
Varun Alagh: "We are paranoid about quality in this company. We started as a baby care company, we used to make products for our own babies. And we still continue to test everything ourselves as well."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Company growth | 20% plus value growth CAGR | Next 3 years; FY25 included |
| EBITDA margin expansion | At least 150 bps improvement over FY24 | FY25 |
| Distribution transition drag | 50-100 bps primary sales impact per quarter; super stockist layer reduced from 50% to 30% | Next 3 quarters |
| Mamaearth growth | Double-digit value CAGR | Next 2 years |
| Derma Co offline contribution | Reach high single digits | FY25 |
| Cosmogenesis Labs deal closure | Acquisition completed | Next 4-6 weeks |
| Saudi legal appeal filing | Appeal filed against court of first instance judgment | Within 30 days |
| Derma Co revenue milestone | Enter INR1,000 crores club | Next 3-5 years |
| Aqualogica and Dr. Sheth's revenue milestone | Enter INR500 crores club each | Next 3-5 years |
| BBlunt revenue milestone | Enter INR250 crores club | Next 3-5 years |
Key Metrics
| Metric | Q4 FY24 |
|---|---|
| Revenue growth (like-for-like) | 23%, with underlying volume growth of 27% |
| Underlying volume growth (UVG) | 27% |
| EBITDA margin | 7%, compared to negative EBITDA in Q4 FY23 |
| Profit after tax (quarterly) | ₹30 cr, highest ever quarterly profit |
| Free cash flow (quarterly) | ₹80 cr |
| Revenue growth (like-for-like, FY24) | 31.5% |
| EBITDA margin (FY24) | 7.1%, improved from 1.5% in FY23 |
| PAT (FY24) | ₹111 cr |
| UVG (FY24) | 41% |
| Free cash flow (FY24) | ₹224 cr |
| Offline channel contribution | ~33% of sales for FY24 |
| NPD contribution to revenue | 18% of FY24 revenue from operations |
| Mamaearth UVG growth (FY24) | Mid-teens |
| The Derma Co ARR (net sales value) | ₹500 cr, GMV close to ₹900 cr |
| Distribution transition impact on primary sales | ~200 bps in Q4, 50–100 bps expected per quarter over next three quarters |
| Super stockist level | ~50% at quarter end, objective to reduce to 30% over next three quarters |
| Mamaearth market share gain (face wash, Nielsen) | 120 bps in FY24 |
| Mamaearth market share gain (shampoo, Nielsen) | 40 bps in FY24 |
| Share among handlers gain (face wash) | 150 bps |
| Share among handlers gain (shampoo) | 65 bps |
| Honasa sunscreen market share (ecommerce) | >30% |
| Active-based subcategory size | ~₹2,000 cr ARR |
| Derma Co + Dr. Sheth's share of active-based subcategory | 33–35% |
| Baby care salience for Mamaearth | ~10% |
| Skin segment share of company value | >60%, fastest-growing segment |
| Modern trade and institutional share within offline | ~40%, GT ~60% |
| FY25 margin improvement target | At least 150 bps improvement over FY24 |
| FY25 growth target | 20%+ CAGR |